Traders should watch for the PLATEAU interim analysis in Q1 2027 as a major catalyst; near-term price action may be driven by pipeline progress expectations rather than financial results. Consider current cash runway and potential need for further financing in 2027.
Price Chart
Executive Summary
Veru reported fiscal Q3 2026 results with a net loss of -$0.30 per share, beating the -$0.32 consensus by 6.3%. The key catalyst was the full enrollment of the Phase 2b PLATEAU trial with 239 patients (exceeding the 200 target) and a clinical supply agreement with Novo Nordisk. Operations are funded by $23.9M cash, sufficient for interim data readouts in calendar Q1 2027.
Key Financial Metrics
Key Facts
- EPS beat consensus: -$0.30 actual vs -$0.32 estimate (6.3% beat)
- Phase 2b PLATEAU trial fully enrolled with 239 patients (target was 200)
- Clinical supply agreement with Novo Nordisk inked for PLATEAU trial
- USPTO Notice of Allowance for enobosarm + semaglutide patent extending protection to October 2044
- Cash position $23.9M at June 30, 2026, up from $15.8M at September 30, 2025
- Net loss narrowed to $7.0M from $7.3M year-over-year
- Interim analysis of PLATEAU trial expected in Q1 2027, topline data in Q4 2027
Financial Impact
Beat consensus EPS by $0.02 (6.3%), net loss reduced by $0.3M YoY. Cash burn rate manageable with $23.9M funding operations into key data milestones.
Risk Factors
- Pro-forma net loss continues with no near-term revenue generation expected
- Phase 2b PLATEAU trial may not replicate prior QUALITY study results
- Novo Nordisk supply agreement subject to 60-day termination for convenience
- Cash burn of ~$20.6M in 9M FY2026 suggests ~9 months runway at current rate
- SEC 'baby shelf' rule limits ability to raise capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | 8-K | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Aug 10, 2026 11w ago | Press Release | $2.77 $2.79 | ▲ +0.72% | ▲ +1.04% | $2.28 (−17.69%) |
Jul 2, 2026 16w ago | 8-K / 424B5 | $3.06 $2.83 | ▲ +7.52% | ▲ +8.39% | $2.28 (+25.49%) |
Jun 4, 2026 20w ago | 8-K | $4.23 $3.40 | ▼ −19.62% | ▼ −17.02% | $2.28 (−46.10%) |
May 13, 2026 23w ago | 8-K | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
May 13, 2026 23w ago | Press Release | $2.26 $2.09 | ▼ −7.52% | ▼ −8.30% | $2.28 (+0.88%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
Apr 7, 2026 29w ago | S-3 | $2.55 $2.43 | ▲ +4.71% | ▲ +5.28% | $2.28 (+10.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers